HCW ups Calithera price target to $14

HCW ups Calithera price target to $14

H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on March 28.

Read More

IntelGenx gets oral film exclusivity for tadalafil ED dosing patent

IntelGenx gets oral film exclusivity for tadalafil ED dosing patent

IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that Eli Lilly granted IntelGenx’s VersaFilm an exclusive license for a tadalafil film product under its 6,943,166 erectile dysfunction (ED) dosing patent. Any exclusivity associated with the tadalafil compound patent expiring is not affected by this agreement.  

Read More

Ortho RTi presents 4 studies at ORS meeting

Ortho RTi presents 4 studies at ORS meeting

Ortho Regenerative Technologies presented results of four key scientific studies at the 2017 Orthopaedic Research Society annual meeting in San Diego, validating its product's ability to improve the repair of three distinct joint tissues: rotator cuff tendons, the meniscus and articular cartilage.

Read More

HCW ups Verastem price target to $6.50

HCW ups Verastem price target to $6.50

H.C. Wainwright raised its price target for Verastem (NASDAQ:STM) to $6.50 from $5, ahead of a highly anticipated top-line readout from the Phase 3 DUO study of duvelisib for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) expected in mid-2017. The stock closed at $1.51 on March 23.

Read More

Vital Therapies prices $35-million stock offering

Vital Therapies prices $35-million stock offering

Vital Therapies (NASDAQ:VTL) has priced a public offering of 8,750,000 newly issued common share at a price of $4 each for gross proceeds of approximately $35-million. 

Read More

3DS TeloView identifies and stages AD patients

3DS TeloView identifies and stages AD patients

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) announced that clinical study results confirm that based on a swab from the inside of a patient’s cheek, its TeloView software platform has the ability to identify patients with Alzheimer’s disease (AD) and also distinguish between mild, moderate, and severe forms of the disease.

Read More

HCW downgrades Proteon to neutral

HCW downgrades Proteon to neutral

H.C. Wainwright downgraded Proteon Therapeutics (NASDAQ:PRTO) to “neutral” from “buy” and slashed its price target to $3 from $18, citing a lack of major catalysts that will likely render the shares range-bound. The stock closed at $1.75 on March 16.

Read More

3DS makes final patent payment

3DS makes final patent payment

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) recently made the final payment to CancerCare Manitoba (CCMB) for the purchase of intellectual property. All patents were assigned from CCMB to 3DS in June 2014.

Read More

Jaguar seeks MUMS designation for EID in dogs

Jaguar seeks MUMS designation for EID in dogs

Jaguar Animal Health (NASDAQ:JAGX) has submitted a formal request to the FDA’s Center for Veterinary Medicine for a determination whether Canalevia qualifies under the requirements of the Minor Use and Minor Species (MUMS) Animal Health Act for the indication of exercise-induced diarrhea (EID) in dogs.

Read More

Aurinia prices $150.5-million stock offering

Aurinia prices $150.5-million stock offering

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has priced a public offering of 22.3 million common shares at a price of $6.75 each for gross proceeds of about $150.5 million.

Read More